Request Sample Inquiry
Short Bowel Syndrome Market

Short Bowel Syndrome Market

Short Bowel Syndrome Market - Global Industry Assessment & Forecast

img
Biotechnology and Life Sciences
Number Of Pages # Pages:

160

Base Year:

2022

Date

Feb - 2022

Format:

PDF XLS PPT

Report Code:

VMR-1318

Segments Covered
  • By Drug Class By Drug Class GLP-2, Growth Hormone, Glutamine, Others
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 1.18 Billion
Revenue 2030Revenue 2030: USD 4.44 Billion
Revenue CAGRRevenue CAGR (2023 - 2030): 18.00%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Short Bowel Syndrome Market - Segment Analysis
    1. Overview
    2. Global Short Bowel Syndrome Market, 2016 - 2028 (USD Million)
    3. Global Short Bowel Syndrome Market - by Drug Class
      1. By GLP-2
      2. By Growth Hormone
      3. By Glutamine
      4. By Others
    4. Global Short Bowel Syndrome Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    5. Market comparative analysis
  4. North America Short Bowel Syndrome Market - Segment Analysis
    1. Overview
    2. North America Short Bowel Syndrome Market, 2016 - 2028 (USD Million)
    3. North America Short Bowel Syndrome Market, by Drug Class
      1. By GLP-2
      2. By Growth Hormone
      3. By Glutamine
      4. By Others
    4. North America Short Bowel Syndrome Market, by Country
      1. U.S.
        1. U.S. Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      2. Canada
        1. Canada Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      3. Mexico
        1. Mexico Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
  5. Europe Short Bowel Syndrome Market - Segment Analysis
    1. Overview
    2. Europe Short Bowel Syndrome Market, 2016 - 2028 (USD Million)
    3. Europe Short Bowel Syndrome Market, by Drug Class
      1. By GLP-2
      2. By Growth Hormone
      3. By Glutamine
      4. By Others
    4. Europe Short Bowel Syndrome Market, by Country
      1. Germany
        1. Germany Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      2. UK
        1. UK Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      3. France
        1. France Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      4. Spain
        1. Spain Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      5. Italy
        1. Italy Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      6. BENELUX
        1. BENELUX Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      7. Rest of Europe
        1. Rest Of Europe Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
  6. Asia Pacific Short Bowel Syndrome Market - Segment Analysis
    1. Overview
    2. Asia Pacific Short Bowel Syndrome Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Short Bowel Syndrome Market, by Drug Class
      1. By GLP-2
      2. By Growth Hormone
      3. By Glutamine
      4. By Others
    4. Asia Pacific Short Bowel Syndrome Market, by Country
      1. China
        1. China Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      2. Japan
        1. Japan Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      3. India
        1. India Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      4. South Korea
        1. South Korea Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      5. South East Asia
        1. South East Asia Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
  7. Latin America Short Bowel Syndrome Market - Segment Analysis
    1. Overview
    2. Latin America Short Bowel Syndrome Market, 2016 - 2028 (USD Million)
    3. Latin America Short Bowel Syndrome Market, by Drug Class
      1. By GLP-2
      2. By Growth Hormone
      3. By Glutamine
      4. By Others
    4. Latin America Short Bowel Syndrome Market, by Country
      1. Brazil
        1. Brazil Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      2. Argentina
        1. Argentina Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      3. Rest of Latin America
        1. Rest of Latin America Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
  8. Middle East & Africa Short Bowel Syndrome Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Short Bowel Syndrome Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Short Bowel Syndrome Market, by Drug Class
      1. By GLP-2
      2. By Growth Hormone
      3. By Glutamine
      4. By Others
    4. Middle East & Africa Short Bowel Syndrome Market, by Country
      1. GCC Countries
        1. GCC Countries Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      2. South Africa
        1. South Africa Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Short Bowel Syndrome Market, By Drug Class
          1. By GLP-2
          2. By Growth Hormone
          3. By Glutamine
          4. By Others
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. TAKEDA Inc (Japan)
    2. Nutrinia (Netherlands)
    3. OxThera (Sweden)
    4. VectivBio AG (Switzerland)
    5. Ardelyx (US) are the major companies operating in Short Bowel Syndrome Market.
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
FAQ
Frequently Asked Question

  • The global Short Bowel Syndrome valued at USD 1.18 Billion in 2022 and is expected to reach USD 4.44 Billion in 2030 growing at a CAGR of 18.00%.

  • The prominent players in the market are TAKEDA Inc (Japan), Nutrinia (Netherlands), OxThera (Sweden), VectivBio AG (Switzerland), Ardelyx (US) are the major companies operating in Short Bowel Syndrome Market..

  • The market is project to grow at a CAGR of 18.00% between 2023 and 2030.

  • The driving factors of the Short Bowel Syndrome include

    • Rise in Prevalence of Short Bowel Syndrome

  • North America was the leading regional segment of the Short Bowel Syndrome in 2022.

Related Reports
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies Privacy Policy